Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

The Hydroponics Company progresses cannabis growing and distribution model

Stage I includes greenhouses for indoor cultivation and growth of medicinal cannabis.
Picture of a facility that could be used for growing plants
The first stage of its research and development facility in Queensland is completed

The Hydroponics Co Ltd (ASX:THC) has completed stage I of its research and development facility and growing capability in Queensland.

Since October 2017, the company has increased the investment in, and focus upon, the development of the Queensland site.

A premium growing facility that will focus on the production of high-quality medicinal cannabis has been established.

David Radford, chief executive officer, said: “We look forward to being granted the manufacturing licence and final approvals.

“These will allow us to commence the growing and manufacturing program of high-quality medicinal products”.

New site allows for increasing demand

The site has been developed to allow for increasing demand for high-quality medicinal cannabis products in both local and export markets.

Stage I of the development includes greenhouses for indoor cultivation and growth of medicinal cannabis.

It also has a drying and shredding facility for the initial processing of the dried plants, and an extraction laboratory for the processing of crude extract from the shredded plants.

The site will provide an onsite laboratory for the development of new strains, as well as testing and quality control of harvested products.

Vertically integrated business model

The current site, when fully optimized, will be scalable to meet the demands of a growing market.

THC plans to vertically integrate along the industry value chain by producing a high quality, processed product.

This will differentiate The Hydroponics Company from companies focused solely upon the production of medicinal cannabis as an agricultural commodity.

Stage II to focus on processing of raw material

Stage II of the company’s growth plan will focus on the processing of raw material into higher value medicinal cannabis oils for use in Australia and overseas.

These products will be provided to approved Australian patients through the National Access Cannabis (NAC) clinics in Australia as a branded product.

There will also be the opportunity to promote other premium products sourced from the company’s international partners.

Discussions have commenced with NAC Canada to supply high-quality Canndeo products to supplement NAC’s existing product portfolio.

Management is also considering an acquisition in Canada.

READ: The Hydroponics Company assesses Canadian entity with C$20 million a year in revenues

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.
Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
PreveCeutical Medical bidding to be big player in preventive healthcare
October 10 2017
Van Deventer aims to grow the firm's valuation from its current $40mln market cap to $1bn plus in the next few years

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use